WO2025215618 - METHODS AND REAGENTS FOR TREATING OR PREVENTING EBV
National phase entry is expected:
Publication Number
WO/2025/215618
Publication Date
16.10.2025
International Application No.
PCT/IB2025/053876
International Filing Date
14.04.2025
Title **
[English]
METHODS AND REAGENTS FOR TREATING OR PREVENTING EBV
[French]
PROCÉDÉS ET RÉACTIFS POUR LE TRAITEMENT OU LA PRÉVENTION DU VIRUS D'EPSTEIN-BARR
Applicants **
SEQIRUS INC.
Inventors
CAI, YongFei
CHEUNG, Michael
HINOSTROZ, Karen Segovia
CHANG, Cheng
RAMANATHAN, Palaniappan
VALIVETI, Chaitanya
VELAZQUEZ, Andrea
MA, Wenchuan
Priority Data
63/633,215
12.04.2024
US
63/633,224
12.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4065 | |
| EPO | Filing, Examination, Granting | 33026 | |
| Japan | Filing, Examination, Granting | 3236 | |
| South Korea | Filing, Examination, Granting | 4497 | |
| USA | Filing, Examination, Granting | 16610 |
Total:
61,434
Contact Us
Abstract[English]
The present disclosure relates to Epstein-Barr Virus (EBV) (human herpesvirus 4) antigens. Specifically, proteins and uses thereof, and self-amplifying mRNA (sa-mRNA) encoding an EBV antigen and uses thereof. The present disclosure relates to vaccines and therapeutic agents, and production and uses thereof.[French]
La présente divulgation concerne des antigènes du virus d'Epstein-Barr (EBV) (virus de l'herpès humain de type 4). Spécifiquement, des protéines et leurs utilisations, et de l'ARNm auto-amplifiant (ARNm-aa) codant pour un antigène EBV et leurs utilisations. La présente divulgation concerne des vaccins et des agents thérapeutiques, et leur production et leurs utilisations.